Every 10-Q that CHARLIES HOLDINGS INC (CHUC) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow CHUC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CHUC filings page.
Charlie’s Holdings, Inc. reported strong top-line growth but continued losses for the quarter ended June 30, 2026. Product revenue rose to $3.8 million from $1.8 million a year earlier, and six‑month revenue increased to $8.6 million from $3.3 million, driven largely by nicotine-based and SBX alternative alkaloid vapor products. Gross profit for the first half improved to $2.3 million, but higher general and administrative plus sales and marketing costs led to a six‑month operating loss of $2.2 million and a net loss from continuing operations of $2.7 million.
Liquidity remains tight. Cash was $0.5 million at June 30, 2026, with net cash used in continuing operating activities of $1.5 million in the first half. Working capital improved to $4.7 million, helped by equity raises in February and May totaling $10.9 million of common shares at $0.20 per share (combined consideration, including cash and settlement of debt and payables). Total assets were $12.8 million and stockholders’ equity was $3.1 million; notes payable totaled $2.15 million, mainly a $2.0 million secured note due 2027 and a $150,000 SBA disaster loan.
The company operates in a highly regulated environment. Its subsidiary is challenging FDA Marketing Denial Orders on certain nicotine and synthetic nicotine products; court-ordered stays currently keep affected PMTAs in pending status, allowing continued sales where state law permits. Management highlights growth plans around SBX Metatine‑based products, expansion of PACHA/Pachamama brands, development of AI‑based age‑gating technology, and international sales. Despite ongoing losses, management believes the company is adequately capitalized to meet obligations for at least the next twelve months.
Charlie’s Holdings, Inc. reported much stronger sales but continued losses for the quarter ended March 31, 2026. Product revenue rose to about $4.8 million from $1.6 million, driven mainly by nicotine and alternative-alkaloid vapor products such as SBX disposables. Gross profit increased, yet higher general and administrative, sales, and marketing costs kept the company at an operating loss of roughly $975,000 and a net loss of about $1.05 million.
Liquidity improved compared with year-end, with working capital of around $4.8 million, cash of $640,000, and stockholders’ equity of $3.1 million. A February 2026 private placement of 3.55 million shares at $0.20 per share raised $710,000, partly through debt forgiveness, reducing outstanding notes. Management believes prior PMTA asset sales to a large tobacco company and ongoing cost and growth initiatives support at least 12 months of operations, though the regulatory environment for vapor products remains a significant uncertainty.
Charlie’s Holdings, Inc. (CHUC) reported a sharp improvement in results for the nine months ended September 30, 2025. Net product revenue rose to $11.9 million from $6.7 million, while gross profit increased to $3.0 million. The company generated net income of $4.4 million versus a $3.0 million loss a year earlier, largely driven by a $7.5 million gain on the sale of PACHA synthetic products and related PMTA assets to R.J. Reynolds Vapor Company.
Cash increased to $1.2 million, and working capital swung to a $3.1 million surplus from a deficit, but operating activities used $6.2 million of cash. Management still cites substantial doubt about the company’s ability to continue as a going concern without additional revenue growth or financing. At September 30, 2025, stockholders’ equity improved to $3.2 million, and common shares outstanding were 270.6 million.
Strategically, Charlie’s is pushing Metatine-based SBX disposable vapes and other alternative alkaloid products, securing more than $6 million in purchase orders at the October 2025 NACS show, including a single $4.4 million SBX order. The company also received an FDA Marketing Denial Order on certain PMTAs but obtained a temporary administrative stay from a federal appeals court and plans to contest the decision. The Don Polly variable interest entity will be wound down.